Skip to main content

Oncology news

21-10-2016 | Non-small-cell lung cancer | Highlight | Article

Editor's pick

KEYNOTE-024 demonstrates pembrolizumab superiority for PD-L1-positive NSCLC

Pembrolizumab is superior to platinum-based chemotherapy for the first-line treatment of advanced non-small-cell lung cancer expressing programmed death-ligand 1 in at least 50% of cells, KEYNOTE-024 results show.


N Engl J Med; Advance online publication, ESMO 2016; Copenhagen, Denmark

27-10-2016 | Chronic myeloid leukaemia | News | Article

MATE1 protein crucial for imatinib uptake

Cellular uptake of the tyrosine kinase inhibitor imatinib may be regulated by the multidrug and toxin extrusion protein 1, suggests research published in Blood Cancer Journal.


Blood Cancer J 2016; 6: e470

27-10-2016 | Chronic myeloid leukaemia | News | Article

CML patient motivation for TFR remission attempts highlighted

Researchers have reviewed the feasibility of, and motivation for, treatment-free remission in chronic myeloid leukaemia  patients with a deep molecular response to tyrosine kinase inhibitor therapy.


Leuk Lymphoma 2016; 57: 2739–2751

27-10-2016 | Chronic myeloid leukaemia | News | Article

IL-1 signalling key for leukaemic stem cell maintenance in CML

Preclinical research suggests that interleukin-1–mediated inflammatory signalling is crucial for the maintenance of chronic myeloid leukaemia stem cells persisting after treatment with tyrosine kinase inhibitors.


Blood 2016; Advance online publication

25-10-2016 | Breast cancer | News | Article

Ribociclib addition boosts hormone-dependent advanced breast cancer PFS

Women with hormone receptor-positive, HER2-negative advanced breast cancer derive a significant progression-free survival benefit from the addition of ribociclib to letrozole in the first-line setting, shows the placebo-controlled MONALEESA-2 trial.


N Engl J Med 2016; Advance online publication; ESMO 2016; Copenhagen, Denmark

Local Consolidative Therapy Boosts Oligometastatic NSCLC PFS

Non-small-cell lung cancer patients with a maximum of three metastatic lesions derive a progression-free survival benefit from local consolidation treatment involving radiotherapy or resection

Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

approvalsWatch: Oncology

ESMO 2016 coverage


medwireNews brings you news and conference reports from the ESMO 2016 Congress, held in Copenhagen, Denmark.

Click through to read the full reports of the latest research.

Twitter Icon Follow medwireNews

Click here
image credits